Term
Duloxetine HCl
FDA Indications |
|
Definition
1. Major depressive disorder (MDD)
2. Management of neuropathic pain associated with diabetic peripheral neuropathy
3. Generalized anxiety disorder (GAD) |
|
|
Term
| Fluoxetine HCl FDA indications |
|
Definition
1. Depression
2. OCD
3. Bulimia nervosa
4. Panic disorder w/ or w/o agoraphoia (fear of leaving home) |
|
|
Term
Sertraline HCl
FDA indications |
|
Definition
1. Depression and OCD
2. Panic disorder w/ or w/o agoraphobia and PTSD
3. PMDD
4. SAD |
|
|
Term
| Amitriptyline HCl FDA indications |
|
Definition
Relief of the sxs of depression
NOT RECOMMENDED FOR CHILDREN < 12 y/o |
|
|
Term
Citalopram HBr
FDA indications |
|
Definition
|
|
Term
Escitalopram Oxalate
FDA indications |
|
Definition
|
|
Term
| Trazodone HCl FDA indications |
|
Definition
Depression w/ or w/o associated anxiety
NOT RECOMMENDED FOR CHILDREN < 18 y/o |
|
|
Term
Venlafaxine HCl
FDA indications |
|
Definition
1. Depression
2. GAD
3. SAD |
|
|
Term
Bupropion HCl
FDA indications |
|
Definition
| Depression and prevention of seasonal major depressive episodes in pts w/ seasonal affective disorders |
|
|
Term
Donepezil HCl
FDA indications |
|
Definition
| Mild, moderate & severe dementia of the Alzheimer's type |
|
|
Term
Quetiapine Fumerate
FDA indications |
|
Definition
1. Schizo
2. Depressive episodes associated w/ bipolar disorder
3. Acute manic episodes associated w/ bipolar I disorder, as monotherapy or adjunct therapy to Li or Divalproex |
|
|
Term
Aripiprazole
FDA indications |
|
Definition
1. Schizo
2. Acute manic and mixed episodes associated w/ bipolar disorder |
|
|
Term
| Risperidone FDA indications |
|
Definition
1. Schizo
2. Short-term tx of acute manic or mixed episodes associated w/ Bipolar I disorder
3. Tx of irritability associated w/ autistic disorder, including sxs of aggression towards others, deliberate self-injuriousness, temper tantrums and quickly changing moods |
|
|
Term
Pregabalin
FDA indications |
|
Definition
1. Neuropathic pain associated w/ diabetic peripheral neuropathy
2. Postherpetic neuralgia
3. Adjunctive therapy for adult pts w/ partial onset seizures
4. Management of fibromyalgia |
|
|
Term
Lamotrigine
FDA indications |
|
Definition
1. Adjunctive therapy in pediatric & adult pts w/ partial seizures or generalized seizures of Lennox-Gastaut syndrome & in primary generalized tonic-clonic seizures
2. Conversion to monotherapy in adults w/ parital seizures who are receiving tx w/ a single EIAED or valproate
3. Maintance tx of Bipolar I Disorder to delay the time to occurrence of mood episodes |
|
|
Term
| Gapabentin FDA indications |
|
Definition
1. Adjunctive therapy in the tx of partial sezures w/ and w/o secondary generalization in adults w/ epilepsy
2. Adjunctive therapy in the tx of partial seizures in pediatric pts age 3-12 y/o
3. Tx of postherpetic neuralgia in adults |
|
|
Term
| Clonazepam FDA indications |
|
Definition
| Lennox-Gastaut Syndrome (petit mal variant), akinetic and myoclonic seizures, and in pts w/ absence seizures (petit mal) who have failed to respond to succinimides |
|
|
Term
Topiramate
FDA indications |
|
Definition
1. Adjunctive and monotherapy for adults and pediatric pts ages 2-16 y/o w/ partial onset seizures, or primary generalized tonic-clonic seizures, and in pts > 2 y/o with seizures associated with Lennox-Gastaut syndrome
2. Initial monotherapy tx of partial onset or primary generalized tonic-clonic seizures in pts > 10 y/o
3. Prophylaxis of migraine HA in adults |
|
|
Term
Divalproex Na
FDA indications |
|
Definition
1. Simple (petit mal), complex absence, and complex partial seizures
2. Acute mania or mixed episodes associated with bipolar disorder, w/ or w/o psychotic features
3. Prophylaxis of migraine HAs |
|
|
Term
|
Definition
1. Management of anxiety disorders or for the short-term relief of the sxs of anxiety
2. Withdrawal sxs of acute alcoholism
3. Relief of skeletal muscle spasm
4. Adjunct in convulsive disorderrs
5. Preoperative apprehension and anxiety
6. Endoscopy procedures
7. Cardioversion
8. Status epilepticus |
|
|
Term
Alprazolam
FDA indications |
|
Definition
1. Anxiety disorders or for the short term relief of sxs of anxiety or anxiety-associated depressive states
2. Tx of panic disorder
3. Tx of panic disorder, w/ or w/o agoraphobia |
|
|
Term
|
Definition
1. Anxiety disorders or for the short-term relief of the sxs of anxiety or anxiety-associated depressive states
2. Insomnia due to anxiety or transient situational stress
3. Preanesthetic medication
4. Sedation and relief of anxiety
5. Status epilepticus
6. ATIVAN INJECTION IS NOT RECOMMENDED FOR CHILDREN < 18 y/o |
|
|
Term
Zolpidem Tartrate
FDA indications |
|
Definition
| Short-term tx of insomnia |
|
|
Term
Carisoprodol
FDA indications |
|
Definition
| Acute, painful musculoskeletal conditions |
|
|
Term
Propoxyphene Napsylate w/ Acetaminophen
FDA indications |
|
Definition
Mild to moderate pain w/ or w/o fever
NOT RECOMMENDED FOR USE IN CHILDREN |
|
|
Term
Oxycodone w/ Acetaminophen
FDA indications |
|
Definition
| Moderate or moderately severe pain |
|
|
Term
Oxycodone HCl
FDA indications |
|
Definition
| Moderate to severe pain where use of an opioid analegsic is appropriate for more than a few days |
|
|
Term
Hydrocodone Bitartrate w/ Acetaminophen
FDA indications |
|
Definition
| Moderate to moderately severe pain |
|
|
Term
Tramadol HCl
FDA indications |
|
Definition
1. Moderate to moderately severe pain
2. Moderate to moderately severe pain in pts who require around the clock tx for an extended period of time |
|
|
Term
|
Definition
1. Mild to moderate pain, primary dysmenorrhea, acute tendinitis, and bursitis
2. RA, OA, and ankylosing spondylitis
3. Acute Gout
NOT RECOMMENDED IN PEDIATRIC |
|
|
Term
|
Definition
1. Mild to Moderate pain and primary dysmenorrhea
2. RA, OA
3. JA |
|
|
Term
|
Definition
1. OA and RA
2. Pauciarticular and polyarticular course JRA |
|
|
Term
Cyclobenzaprine HCl
FDA indications |
|
Definition
Skeletal muscle spasms
NOT RECOMMENDED FOR CHILDREN < 15 y/o |
|
|
Term
Fenofibrate
FDA indications |
|
Definition
1. Adjunctive therapy to diet to reduce elevated LDL-C, Total-C, TGs and Apo B, and to increase HDL-C in adult pts w/ primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
2. Adjunctive therapy to diet for tx of adult pts w/ hyperTG (Fredrickson Types IV and V)
3. Tx of ts w/ renal impairment |
|
|
Term
Rosuvastatin Ca
FDA indications |
|
Definition
Fredrickson Type IV, primary dysbetalipoproteinemia (Fredrickson type III), increase HDL-C in pts w/ hypercholesterlemia (heterozygous familial & nonfamilial) and mixed dyslipidemia (Type IIa & IIb)
2. Homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering txs
3. Adjunct to diet to slow the progession of atherosclerosis |
|
|
Term
Atorvastatin Ca
FDA indications |
|
Definition
1. Frederickson Type IIa, IIb, III, & IV, multiple CHD riskfactorss to reduce the risk of MI, angina, and revascularization procedures
2. Reduce the risk of non-fatal MI, fatal or nonfatal stroke, angina, revascularization, & hospitalization for CHF
3. Homozygous familial hypercholesterolemia
4. Boys & Girls 10-17 w/ heerozygous familial hypercholesterolemia if adequate diet therapy remains > 190 or > 160 AND there is a family hx of premature CVD or 2 or more CVD risk factors |
|
|
Term
Lovastatin
FDA indications |
|
Definition
1. Fredrickson Type IIa & IIb
2. Slow progression of coronary atherosclerosis in CHD pts
3. Primary prevention of CHD in pts w/o symptomatic CVD who have avg to moderately elevated TC and LDL & below avg of HDL
4. Boys & Girls 10-17 w/ heerozygous familial hypercholesterolemia if adequate diet therapy remains > 190 or > 160 AND there is a family hx of premature CVD or 2 or more CVD risk factors |
|
|
Term
Simvastatin
FDA indications |
|
Definition
1. Frederickson Type IIa, IIb, III, & IV
2. Homozygous familial hypercholesterolemia
3. Boys & Girls 10-17 w/ heerozygous familial hypercholesterolemia if adequate diet therapy remains > 190 or > 160 AND there is a family hx of premature CVD or 2 or more CVD risk factors |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Pioglitazone HCl
FDA indications |
|
Definition
| T2DM alone and in combo w/ sulfonylurea, metformin or insulin, when diet and exercise + the single agent does not result in adequate glycemic control |
|
|
Term
Insulin Glargine, rDNA origin
FDA indications |
|
Definition
|
|
Term
Metformin HCl
FDA indications |
|
Definition
|
|
Term
Lisinopril
FDA indications |
|
Definition
1. HTN
2. Adjunctive therapy in CHF in pts not responding adequately to diuretics and digitalis
3. Tx of hemodynamically stable pts w/in 24 h of acute MI |
|
|
Term
Lisinopril w/ HCTZ
FDA indications |
|
Definition
|
|
Term
Metoprolol Succinate
FDA indications |
|
Definition
1. HTN
2. Long-term tx of angina pectoris
3. Tx of stable symptomatic (NYHA class ii or iii) HF of ischemic, hypertensive, or cardiomyopathic origin |
|
|
Term
Metoprolol Tartrate
FDA indications |
|
Definition
|
|
Term
|
Definition
1. HTN
2. Angina pectoris
3. Acute MI
4. Severe renal impairment |
|
|
Term
Carvediolol
FDA indications |
|
Definition
1. HTN
2. mild to moderate HF of ischemic or cardiomyopathic origin, in combo w/ digitalis, diuretics and and ACEI
3. LVEF of < 40% following MI |
|
|
Term
Amlodipine Besylate
FDA indications |
|
Definition
1. HTN
2. Chronic stable or vasospastic angina |
|
|
Term
Clonidine HCl
FDA indications |
|
Definition
|
|
Term
Diltiazem HCl
FDA indications |
|
Definition
1. Angina pectoris due to coronary artery spasm and chronic stable angina
2. HTN
3. Temporary control of a-fib or a-flutter and rapid conversion of paroxysmal supraventricular tachy to sinus rhythm |
|
|
Term
|
Definition
1. Adjunctive therapy in edema associated w/ CHF, hepatic cirrhosis, corticosteroid and estrogen therapy or various forms of renal dysfx
2. HTN |
|
|
Term
Spironolactone
FDA indications |
|
Definition
1. Edema due to CHF or nephrotic syndrome & cirrhosis of the liver accompanied by edema &/or ascites
2. HTN
3. Dx of primary hyperaldosteronism
4. Tx of primary hyperaldosteronism in pts unsuitable for surgery |
|
|
Term
Furosemide
FDA indications |
|
Definition
1. Edema-associated CHF, cirrhosis of the liver and renal disease
2. HTN
3. Acute pulmonary edema |
|
|
Term
Tiotropium Br
FDA indications |
|
Definition
| Long-term QD maintenance tx of bronchospasm associated w/ COPD (chronic bronchitis & emphysema) |
|
|
Term
Levalbuterol HCl
FDA indications |
|
Definition
1. Bronchospasm 6-11 y/o w/ reversible obstructive airway disease
2. Bronchospasm > 12 y/o w/ reversible obstructive airway disease
3. Prevention or tx of bronchospasm in > 4 y/o reversible obstructive disease |
|
|
Term
Ipratropium Br w/ Albuterol Sulfate
FDA indications |
|
Definition
|
|
Term
| Fluticasone Propionate w/ Salmeterol Xinafoate |
|
Definition
|
|
Term
Albuterol Sulfate
FDA indications |
|
Definition
1. Bronchospasm w/ reversible obstructive airway disease
2. Prevention of exercise-induced bronchospasm |
|
|
Term
Montelukast Na
FDA indications |
|
Definition
1. Prophylaxis and chronic tx of asthma > 2 y/o
2. seasonal allergic rhinitis for > 2 y/o
3. Prevention of exercise-induced bronchoconstriction in pts > 15 y/o |
|
|
